contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-strong-cross-read-from-roches-pathai-takeover-nuways-ag-research-r

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

LinkedIn              Development of convolutional neural networks for automated brain-wide...    Speeding up image analysis time from weeks to minutes. ⏱️ That's how AI is transforming preclinical synucleinopathy research.   Traditional characterization of histological samples in neurodegenerative disease research is labor-intensive and...                             New research results from Aiforia regarding the study of mouse brains as well; this likely relates to the investigation of neurological diseases such as Parkinson’s. Need to wade through this when there’s time.

Is there any information at all on the price range of the deal?

Grundium, a company emerging from the camera and computer vision hub in Hervanta, has acquired Aiforia’s competitor, Visiopharm. It seems that firms providing these machine learning models and software are now in high demand.                   Grundium – 21 May 26              Grundium Acquires Visiopharm to Create Integrated Precision Pathology Platform    Grundium has completed the acquisition of Visiopharm, a global leader in AI-driven precision pathology software.         Est. reading time: 4 minutes

This hadn’t been posted here yet, @Antti_Siltanen interviews CEO Jukka Tapaninen: Aiforian kuulumiset: Foundation Enginellä nopeutta ja skaalautuvuutta tuotekehitykseen - Inderes

In that video, Dr. Zuraw praises Aiforia starting at around the 12:30 mark. The case involves assisting Pakistani pathologist Zehra Talat, to which Aiforia responded when others did not. This is also good publicity for Aiforia.

I wonder if we’ll get an announcement about a new directed share issue next week. Last year, the issue was on May 27th, and the year before that, it was on May 22nd. They managed to raise about 10 million from the issue two years ago, and about 8 million from last year’s May issue. Last year, they seemed to raise less than expected because they decided to carry out another issue on December 10th, which brought in about 4.2 million. Additionally, they held change negotiations at the end of the year, from which they estimated annual cost benefits of about 2.5 million. If one estimates that they still need about 10 million in funding annually, then 4.7 million would already be covered for this year (8 + 4.2 + 2.5 - 10). So, would it be enough for this year if they passed the hat around for a bit over 5 million?

The financial figures for unlisted companies are on very uncertain ground, so estimating valuation levels can easily go significantly wrong. A couple of comments: According to some sources (GrowJo, Zoominfo), PathAI’s revenue was ~100 MUSD. These should probably be taken with a fair grain of salt. This would mean a P/S of roughly 10x based on backward-looking figures and the full purchase price. Tempus AI paid 81 MUSD for Paige, primarily in its own shares. 220 MUSD had been invested into Paige. AZ - Modella AI. Purchase price unknown. Evident - Pramana, purchase price unknown. Leica- Indica, investment, details unknown.

Aiforia Technologies

(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately...

(Link updated)<br><br>Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection with the deal. PathAI divested its lab services business to Quest Diagnostics for $ 100m in June 2024. Post-divestment, this could put PathAI's FY25 sales at a range of $ 30-40m, implying a deal valuation of 26-35x sales (incl. earnouts). At Friday close, Aiforia traded at 18.3x EV/S FY25 and 12.4x EV/S FY26 (eNuW).<br><br>Large healthtech companies are betting big on AI. In this context, Aiforia stands out as the leading AI play in clinical oncology diagnostics. We make no changes to our DCF model, and reiterate our BUY rating with a € 3.80 PT.

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)